DelveInsight’s “Oral Mucositis Market Insights, Epidemiology and Market Forecast – 2030” report provides an overview of the disease and market size of Oral Mucositis for the 7MM major pharmaceutical markets, i.e., the United States, EU5 (Germany, France, Italy, Spain, and the United Kingdom), and Japan. This report covers the various treatment practices, and Oral Mucositis forecasted epidemiology from 2020 to 2030, segmented by the 7 major markets.
Some of the key facts of the Oral Mucositis Market Report:
Request for Sample Pages: https://www.delveinsight.com/sample-request/oral-mucositis-om-market
Key benefits of the Oral Mucositis Market Report:
“According to Delveinsight, females appear to be more likely than males to develop Oral mucositis.”
Oral Mucositis (OM) is the most common, debilitating complication of cancer chemotherapy and radiotherapy. It is characterized by inflammation and ulceration in the oral cavity caused by the chemotherapeutic drug substances and radiotherapy used in cancer treatment. The symptoms appear after five to ten days after the chemotherapy treatment or 14 days after the start of radiotherapy. The early symptoms include erythema and light discoloration of the mucosa. As OM progresses, erosive lesions and ulcers are developed.
Mouth sores are extremely painful and are typically the most distressing manifestation. It has significant negative impact on patient’s quality of life (QOL). Potential complications of OM include pain, increased risk of local and systemic infections, bleeding, insufficient food intake, and delays in administration of radiotherapy and/or chemotherapy, dose reduction of the chemotherapy drugs, increased length of hospital stays, associated economic burdens and in some cases life-threatening infections (septicemia in neutropenic cases).
“As per DelveInsight insights, the incidence of Grade I and II OM has been observed to be higher in comparison to Grade III-IV cases across all the major markets”
Some of the Oral Mucositis Companies are:
The launch of the emerging therapies is expected to significantly impact the Oral Mucositis treatment scenario in the upcoming years:-
Oral Mucositis Drugs Covered:
Table of Contents:
1. Key Insights
2. Executive Summary of Oral Mucositis
3. SWOT Analysis of Oral Mucositis
4. Oral Mucositis: Market Share (%) Distribution Overview at a Glance: By Country
5. Epidemiology and Market Methodology
6. Oral Mucositis: Disease Background and Overview
7. Diagnosis of Oral Mucositis
8. Epidemiology and Patient Population
9. Epidemiology Scenario: 7MM
10. The United States Epidemiology
11. EU-5 Epidemiology
12. Current Treatment Practices: Oral Mucositis
13. Prevention of Oral Mucositis
14. Guidelines of Oral Mucositis
15. Unmet Needs
16. Patient Journey of Oral Mucositis
17. Key Endpoints in Oral Mucositis Clinical Trials
18. Marketed Therapies
19. Emerging Therapies
20. Oral Mucositis: Seven Major Market Analysis
21. 7MM Market Size
22. The United States Market Size
23. EU-5 Market Size
24. Market Access and Reimbursement of Oral Mucositis Therapies
25. Market Drivers of Oral Mucositis
26. Market Barriers of Oral Mucositis
27. Appendix
28. DelveInsight Capabilities
29. Disclaimer
30. About DelveInsight
About Delveinsight:
DelveInsight Business Research is a leading Market Research, and Business Consultant focused purely on Healthcare. It helps pharma companies by providing them with end-to-end services to solve their business problems.
Get hold of all the Pharma and healthcare market research reports on our market research subscription-based platform PharmDelve.
Media ContactCompany Name: DelveInsight Business Research LLPContact Person: Ankit NigamEmail: Send EmailPhone: +19193216187Address:304 S. Jones Blvd #2432 City: AlbanyState: New YorkCountry: United StatesWebsite: https://www.delveinsight.com/report-store/oral-mucositis-om-market